// App-Quantinova.ai

POS1051 (2021) : SECUKINUMAB IMPROVES PHYSICAL FUNCTION AND INHIBITS STRUCTURAL DAMAGE IN PsA PATIENTS WITH SUSTAINED REMISSION OR LOW DISEASE ACTIVITY: RESULTS FROM A PHASE 3 STUDY

Researchers

Presenter

  • L. C. Coates

Principal Investigators

  • P. J. Mease

  • D. D. Gladman

  • S. Navarra

  • W. Bao

  • C. Gaillez

Medical Centers

  • Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Oxford, United Kingdom

  • 2Swedish Medical Center/Providence St. Joseph Health and University of Washington, Rheumatology, Seattle, Washington, United States of America

  • Toronto Western Hospital, University of Toronto, Schroeder Arthritis Institute, Ontario, Canada

  • University of Santo Tomas Hospital, Section of Rheumatology, Manila, Philippines

  • Novartis Pharma AG, Immunology, Hepatology and Dermatology Development Unit, Basel, Switzerland

Locations

  • United Kingdom

  • United States

  • Canada

  • Philippines

  • Switzerland

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • Malondialdehyde

Drug/Treatment

  • secukinumab

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Controlled

Phase

  • III

Study Id's

  • NCT02404350

Sponsors

  • Abbvie

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved